The Population Impact of Late Presentation with Advanced HIV Disease and Delayed Antiretroviral Therapy in Adults Receiving HIV Care in Latin America

Abstract

Late presentation to care and antiretroviral therapy (ART) initiation with advanced HIV-disease are common in Latin America. We estimated the impact of these conditions on mortality in the region. We included adults enrolled during 2001-2014 at HIV-care clinics. We estimated the adjusted attributable risk (AR) and population attributable fraction (PAF) for all-cause mortality of presentation to care with advanced HIV-disease (advanced-LP), ART initiation with advanced HIV-disease, and not initiating ART. Advanced HIV-disease was defined as CD4<200 cells/L or AIDS. AR and PAF were derived using marginal structural models. Of 9,229 patients, 56% presented with advanced HIV-disease. ARs of death for advanced-LP were 86%, 71%, and 58%, and PAFs were 78%, 58%, and 43% at 1, 5, and 10 years post-enrollment. Among people without advanced-LP, ARs of death for delaying ART were 39%, 32%, and 37% at 1, 5, and 10 years post-enrollment and PAFs were 20%, 14%, and 15%. Among people with advanced-LP, ART decreased the hazard of death by 63% in the first year post-enrollment, but 93% of these started ART; thus universal ART among them would only reduce mortality by 10%. Earlier presentation to care and earlier ART initiation would prevent most HIV-deaths in Latin America.